#United States #Philadelphia #Securities Fraud #Berger Montague #Hims & Hers

Hims & Hers Health Inc. Faces Securities Fraud Investigation

In a significant development, Berger Montague, a leading law firm recognized for its prowess in securities class action litigation, has initiated an investigation into Hims & Hers Health Inc. (NYSE: HIMS). The inquiry is centered on potential violations of the Securities Exchange Act of 1934, specifically concerning misleading information transmitted to investors related to the Company's regulatory compliance and operational practices.

On June 23, 2025, Hims & Hers faced a sharp drop in stock value—plummeting by over 34%—following the termination of its collaboration with Novo Nordisk. This decline raises alarms for investors and stakeholders, as it reflects the company's precarious standing and potential lack of transparency regarding risk disclosures, particularly related to their compounded drug offerings.

Details of the Investigation

The investigation explores whether investors were adequately informed about the risks associated with their investments in Hims & Hers, especially during a critical period from April 29, 2025 to June 22, 2025. Recent allegations suggest that Hims & Hers did not fully disclose significant operational risks, raising the stakes for affected investors who might consider pursuing legal recourse.

Investors who acquired Hims & Hers stock within the specified time frame may now have the opportunity to take part in a class action lawsuit. Those eligible can seek to attain lead plaintiff status, representing those similarly impacted by the company's decisions and actions. This could lead to potential restitution for damage incurred due to the decline in stock value, arising from the issues being investigated.

How to Proceed

Hims & Hers investors looking for more information about this inquiry are encouraged to reach out to Berger Montague for further guidance. Investors can connect with Andrew Abramowitz by email at [email protected] or by phone at (215) 875-3015, or contact Caitlin Adorni at [email protected] or at (267) 764-4865. The window for pursuing such claims is crucial, as the deadline to act is set for August 25, 2025.

About Berger Montague

Founded in 1970, Berger Montague has established a strong reputation in the field of securities litigation, with regional offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, and Chicago. Over its five-decade-long journey, the firm has advocated on behalf of both individual and institutional investors, underlining its commitment to uphold investor rights and address injustices within the financial markets.

The impending investigation represents an opportunity for affected investors to be informed of their rights and take action against potentially misleading practices of Hims & Hers Health Inc. As the landscape of investor relations evolves, such inquiries highlight the necessity for transparency and accountability in corporate governance.